FDA Approves GE HealthCare’s Flyrcado for Diagnosing Coronary Artery Disease

Flyrcado is the first positron emission tomography myocardial perfusion imaging agent of its kind designed for the detection of coronary artery disease.

Leave a Reply

Your email address will not be published. Required fields are marked *